Citi backs AstraZeneca sentiment boost after Etcamah wins accelerated FDA approval

What Brokers Say Health Written by: Ian Lyall 15:03 Mon 07 Sep 2026 --> Disclaimer No investment advice About this content Editorial Standards & Policies Share article About this content × About Ian Lyall Ian Lyall, a seasoned journalist and editor, brings over three decades of experience to his role as Managing Editor at Proactive. Overseeing Proactive's editorial and broadcast operations across six offices on three continents, Ian is responsible for quality control, editorial policy, and content production. He directs the creation of 50,000 pieces of real-time news, feature articles, and filmed interviews annually. Prior to Proactive, Ian helped lead the business output at the Daily... Read more About the publisher Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. All our content is produced independently by our experienced and qualified teams of news journalists. Proactive news team spans the world’s key finance and investing hubs with bureaus and studios in London, New York, Toronto, Vancouver, Sydney and Perth. We are experts in medium and small-cap markets, we also keep our community up to date with blue-chip companies, commodities and broader investment stories. This is content that excites and engages motivated private investors. The team delivers news and unique insights across the market including but not confined to: biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto and emerging digital and EV technologies. Use of technology Proactive has always been a forward looking and enthusiastic technology adopter. Our human content creators are equipped with many decades of valuable expertise and experience. The team also has access to and use technologies to assist and enhance workflows. Proactive will on occasion use automation and software tools, including generative AI. Nevertheless, all content published by Proactive is edited and authored by humans, in line with best practice in regard to content production and search engine optimisation. AstraZeneca PLC ( LSE:AZN NASDAQ:AZN ) View Price & Profile Citi backs AstraZeneca sentiment boost after Etcamah wins accelerated FDA approval Published: 15:03 07 Sep 2026 BST Citi has flagged AstraZeneca PLC's (LSE:AZN, NASDAQ:AZN) accelerated approval for Etcamah, known chemically as camizestrant, as a meaningful sentiment driver for the shares. The oral selective oestrogen receptor degrader has been cleared by the US Food and Drug Administration in combination with a CDK4/6 inhibitor for hormone receptor positive, HER2 negative metastatic breast cancer. The approval applies once an ESR1 mutation is detected during treatment with an aromatase inhibitor and CDK4/6 inhibitor. It follows a delayed decision date and a negative advisory committee vote of six to three in April, as well as European approval in July. Citi notes the label is broadly in line with expectations, covering use alongside all three major CDK4/6 inhibitors: abemaciclib, palbociclib and ribociclib. Patients must be tested using Guardant360 CDx, an FDA-authorised diagnostic approved simultaneously. As anticipated following the advisory committee hearing, the label carries a boxed warning over QT prolongation and arrhythmia risk, particularly when combined with ribociclib, alongside monitoring requirements. Citi models the underlying SERENA-6 opportunity at $450 million, risk-adjusted down to $112 million. That is dwarfed by the potential $6 billion opportunity from SERENA-4, a trial due in the second half of the financial year that could expand Etcamah into the broader first-line HR positive, HER2-negative population. Citi adds that should SERENA-4 fail, it still sees a $1.5 billion opportunity underpinned by SERENA-6 alone. Continue reading